Came across this article that has the investors knickers all in a bunch.
Mallinckrodt's sales growth has accelerated for three straight quarters, jumping 63% to $909.9 million in the latest period on strong demand for its Acthar Gel, a treatment for multiple sclerosis, and its pain drug Ofirmev. Both drugs were acquired through acquisitions last year.
Read More At Investor's Business Daily: http://ift.tt/1IK8Aem
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
What am I missing? Who are we selling all this wonderful stuff to?
Mallinckrodt's sales growth has accelerated for three straight quarters, jumping 63% to $909.9 million in the latest period on strong demand for its Acthar Gel, a treatment for multiple sclerosis, and its pain drug Ofirmev. Both drugs were acquired through acquisitions last year.
Read More At Investor's Business Daily: http://ift.tt/1IK8Aem
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
What am I missing? Who are we selling all this wonderful stuff to?
What am I missing???
Aucun commentaire:
Enregistrer un commentaire